Bold claim: drugs like Ozempic and other GLP-1 mimetics could cut heart-damage risk after a heart attack, potentially helping about half of patients avoid deadly complications. And this is where it gets controversial: new research suggests a completely different use for these weight-loss medicines beyond their familiar goals.
A study led by researchers at the University of Bristol and University College London (UCL), published in Nature Communications, explores how GLP-1-based drugs might support heart healing after a heart attack. The investigators build on prior work showing these drugs lower the chance of serious heart problems, independent of a person’s existing health conditions or the amount of weight they lose.
What the researchers set out to uncover was the mechanism behind this protective effect. Their earlier work showed that tiny blood vessels inside the heart—pericytes—tend to constrict coronary capillaries right when the heart is starved of oxygen. This constriction can contribute to a condition known as no-reflow, where blood struggles to reach parts of the heart tissue even after the main artery is reopened during emergency treatment. The latest findings indicate that GLP-1 drugs may counteract this problem.
Using animal models, the team observed that GLP-1 medications can enhance blood flow to the heart after a heart attack by activating potassium channels in pericytes, causing these cells to relax. The relaxation widens constricted vessels and reduces the extent of heart damage, potentially lowering the risk of adverse outcomes.
Professor David Attwell of UCL, a co-lead of the study, notes that with several GLP-1 drugs already in clinical use for conditions like type 2 diabetes, obesity, and kidney disease, there may be an opportunity to repurpose these medications to address the risk of no-reflow in heart attack patients. This could represent a life-saving shift in how post‑heart-attack recovery is managed.
The principal author, Dr. Svetlana Mastitskaya of Bristol Medical School, explained that nearly half of heart attack patients experience narrowed tiny blood vessels in the heart that persist after the main artery is cleared, contributing to no-reflow. The new work suggests GLP-1 drugs might prevent this vessel narrowing and the subsequent complications.
The study, titled “GLP-1 activates KATP channels in coronary pericytes as the effector of brain-gut-heart signalling mediating cardioprotection,” is open access in Nature Communications. Funding was provided by the British Heart Foundation.
Controversial note: while the results are promising, they come from animal studies. Translating these findings to humans will require careful clinical testing to confirm safety, effectiveness, and the best treatment windows. Do these results justify broad repurposing of GLP-1 medications for post-heart-attack care, or should they first be confirmed through rigorous human trials? What other factors—such as timing, dosing, and patient comorbidities—could influence whether this approach works in real-world settings? Share your thoughts in the comments.
